Phase I and pharmacokinetic study of Yondelis™ (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours

This publication has 16 references indexed in Scilit:

• The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux
  Nature Medicine, 2001
• Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action
  European Journal Of Cancer, 2001
• Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation
  Proceedings of the National Academy of Sciences, 2000
• Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743
  Proceedings of the National Academy of Sciences, 2000
• High antitumour activity of ET743 against human tumour xenografts from melanoma, non-small-cell lung and ovarian cancer
  Annals of Oncology, 1999
• In vitro antitumor activity of the novel marine agent, Ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients
  Annals of Oncology, 1998
• In vitro schedule-dependency of myelotoxicity and cytotoxicity of Ecteinascidin 743 (ET-743)
  Annals of Oncology, 1998
• The impact of adding low-dose leucovorin to monthly 5-fluorouracil in advanced colorectal carcinoma: Results of a phase III trial
  Annals of Oncology, 1998
• DNA Sequence- and Structure-Selective Alkylation of Guanine N2 in the DNA Minor Groove by Ecteinascidin 743, a Potent Antitumor Compound from the Caribbean Tunicate Ecteinascidia turbinata
  Biochemistry, 1996
• Progress in the acquisition of new marine-derived anticancer compounds: development of ecteinascidin-743 (ET-743)
  Drugs of the Future, 1996